Jun 18 2019 0 Holding(s) in Company https://www.motifbio.com/wp-content/uploads/2019/06/MTFB-TR-1-SAND-GROVE-CAPITAL-MANAGEMENT-LLP-18.06.19.pdf
Jun 14 2019 0 Holding(s) in Company https://www.motifbio.com/wp-content/uploads/2019/06/MTFB-TR-1-Amphion-Innovations-plc-14.05.19.pdf
Jun 12 2019 0 Holding(s) in Company https://www.motifbio.com/wp-content/uploads/2019/06/TR1-Form-10062019-Issuer.pdf
Jun 06 2019 0 Motif Bio Announces Path Forward for Iclaprim following Receipt of FDA Meeting Minutes https://www.motifbio.com/wp-content/uploads/2019/06/MTFB-FDA-meeting-minutes-06.06.19.pdf
May 31 2019 0 Results of Annual General Meeting https://www.motifbio.com/wp-content/uploads/2019/05/20190531_MTFB-Result-of-AGM-FINAL.pdf
May 31 2019 0 Holding(s) in Company https://www.motifbio.com/wp-content/uploads/2019/05/AMP-31-May-2019-notifications-major-interests.pdf
May 29 2019 0 Holding(s) in Company https://www.motifbio.com/wp-content/uploads/2019/05/TR1-Form-28052019-Issuer.pdf
May 22 2019 0 AGM Statement https://www.motifbio.com/wp-content/uploads/2019/05/MTFB-AGM-Statement-22.05.19.pdf
May 22 2019 0 Motif Bio to Evaluate Orphan Disease Opportunity for Iclaprim in Ophthalmology https://www.motifbio.com/wp-content/uploads/2019/05/MTFB-Chorioretinitis-in-vitro-study-22.05.19-FINAL.pdf
May 21 2019 0 Motif Bio to Present Iclaprim Data at ASM Microbe 2019 https://www.motifbio.com/wp-content/uploads/2019/05/MTFB-ASM-2019-Curtain-Raiser-21.05.19.pdf
